Adagrasib (MRTX849) - Moligand™, 10mM in DMSO , GTPase KRas inhibitor, CAS No.2326521-71-3, GTPase KRas inhibitor

CAS: 2326521-71-3 Cat. No.: A408413 Summenformel: C32H35ClFN7O2 Molekulargewicht: 604.12 EG-Nummer: 870-640-0
Zu bestellen verfügbar
QUALITÄT & REINHEIT Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1ml
A408413-1ml
—
2 Auf Lager
66,73€
Enter a quantity for the sizes you want to add.

Übersicht

Information

Adagrasib (MRTX849) Adagrasib (MRTX849) is a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling.
In vitro

To evaluate the breadth of MRTX849 activity, its effect on cell viability is determined across a panel of 17 KRASG12C-mutant and three non-KRASG12C-mutant cancer cell lines using 2D (3-day, adherent cells) and 3D (12-day, spheroids) cell growth conditions. MRTX849 potently inhibits cell growth in the vast majority of KRASG12C-mutant cell lines with IC50 values ranging between 10 nM and 973 nM in the 2D format and between 0.2 nM and 1042 nM in the 3D format..

In vivo

Rapid tumor regression is observed at the earliest posttreatment tumor measurement and animals in the 30 mg/kg and 100 mg/kg cohorts exhibits evidence of a complete response at study Day 15. Dosing is stopped at study Day 16 and all 4 mice in the 100 mg/kg cohort and 2 out of 7 mice in the 30 mg/kg cohort remains tumor-free through study Day 70..
Cell Data

cell lines:

Concentrations:--

Incubation Time:24 h

Powder Purity:≥99%

Spezifikationen

Synonyme
2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
Spezifikationen & Reinheit
Moligand™, 10mM in DMSO
Biochemische und physiologische Mechanismen
Adagrasib (MRTX849) is a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling.
Storage
Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Note
Moligand™
Aktionsart
INHIBITOR
Mechanismus der Wirkung
GTPase KRas inhibitor
Produkteigenschaften
ALogP
5
Namen und Kennungen
Isomere SMILES
CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F
Molekulargewicht
604.12
Reaxys
39485713
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=39485713&ln=

Erweiterte Daten

Zugehörige Ziele (menschlich)
KRAS Tclin GTPase KRas (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Sicherheit und Gefahren (GHS)
Piktogramm(e)
Signal
Warning
Gefahrenhinweise

H227:Combustible liquid

Sicherheitshinweise

P210:Keep away from heat, hot surface, sparks, open flames and other ignition sources. - No smoking.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P370+P378:In case of fire: Use ... to extinguish.

P403+P235:Store in a well-ventilated place. Keep cool.

P501:Dispose of contents/container to an approved waste disposal plant.

Reaxys
39485713
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=39485713&ln=
FAQs und Artikel
Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition
KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past
MAPK/ERK Signaling Pathway: RAS–RAF–MEK–ERK Cascade Regulation, Cellular Functional Outputs, and Research Tool Applications
Protein Degradation-Targeting Chimeras (PROTACs): Molecular Design, Degradation Mechanisms, Experimental Evaluation, and Research Tools
Mechanisms of Action, Design Strategies, and Research Evaluation of Targeted Covalent Inhibitors
Molecular Classification, Oncogenic Drivers, and Resistance Mechanisms of Non-Small Cell Lung Cancer
Why Proximity to Cysteine Does Not Necessarily Lead to Covalent Bond Formation: Warhead Reactivity, Reaction Geometry, and Target-Site Microenvironment
Citations of This Product
Lösungsrechner
Bewertungen

Kundenbewertungen

Benötigen Sie Hilfe bei der Auswahl der Qualität?

Unser Leitfaden zur Qualitätsauswahl behandelt Reinheit, Stabilisatorstatus und Anwendungseignung für alle Varianten in unserem Katalog.

Moligand™ Qualitätsleitfaden ansehen →

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.